Related Experiment Video
Updated: Sep 13, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Tuberous sclerosis complex 2 deficiency in cardiomyocytes exacerbates cardiac remodeling in diabetic mice
Rui-Xue Yang1, Zhan-Hui Du2, Xiu-Hui Song3
1State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Background:
Based on gene expression profiles from the BioGPS database, Tuberous sclerosis complex 2 (Tsc2) exhibited the highest expression in mouse cardiac tissues. Herein, we investigated the potential functional role of Tsc2 in diabetic cardiomyopathy.
Methods And Results:
Cardiac-specific Tsc2 deletion exacerbated myocardial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic mice. Whole-transcriptomic analysis combined with single cell-sequencing analysis from the Human Protein Atlas database demonstrated that Tsc2 deletion enhanced Angiopoietin-like protein 7 (Angptl7) expression in cardiomyocytes under hyperglycemia. Recombinant adeno-associated virus serotype 9 carrying Angptl7 shRNA under cardiac troponin T promoter substantially reversed Tsc2 deletion-induced cardiac remodeling and dysfunction in diabetic mice. Mechanistically, the study demonstrated that cardiomyocyte-released Angptl7 activated β-Catenin in fibroblasts and promoted cardiac fibrosis through a paracrine mechanism. Furthermore, chronic supplementation with leucine, an essential branched-chain amino acid, led to adverse cardiac remodeling and dysfunction through Angptl7 activation in diabetic mice.
Conclusions:
Our findings demonstrate that Tsc2 deficiency in cardiomyocytes disrupts cardiac homeostasis and contributes to the progression of diabetic cardiomyopathy. The results also suggest that targeting Angptl7 represents a potential therapeutic strategy for diabetic cardiomyopathy, particularly in patients with Tsc2 mutation.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology

